Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422494 | 1.00 | DGAT1 (0.35) | DGAT1PKM | |
| SCHEMBL2355959 | 0.81 | CYP2C19 (0.36) | DGAT1 | |
| SCHEMBL27870549 | 0.81 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL7275682 | 0.81 | CYP2C19 (0.36) | DGAT1 | |
| SCHEMBL27743187 | 0.79 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL27638658 | 0.79 | PKM (0.43) | PKM | |
| SCHEMBL3174371 | 0.77 | DGAT1 (0.38) | DGAT1PKM | |
| SCHEMBL365038 | 0.77 | DGAT1 (0.38) | DGAT1PKM | |
| SCHEMBL27769856 | 0.75 | MEN1 (0.34) | — | |
| SCHEMBL1583929 | 0.75 | DGAT1 (0.47) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117209447-A | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117143042-A | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-111094243-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-113286784-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| CN-111094243-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华炎症研究公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2015177537-A1 | PROCESS FOR PREPARING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES AND INTERMEDIATES THEREOF | CIPLA LIMITED (IN) | 2015-11-26 | — | — | WO | disclosed |
| US-20110190306-A1 | Inhibitors of PLK | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2296662-A1 | INHIBITORS OF PLK | Chroma Therapeutics Ltd. (GB) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009130453-A1 | INHIBITORS OF PLK | CHROMA THERAPEUTICS LTD. (GB) | 2009-10-29 | — | — | WO | disclosed |
| CN-101018770-A | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190306-A1 | Inhibitors of PLK | PLK3, PLK2, PLK4 | DGAT1 3020/4885PKM 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.